Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ASTRAZENECA PHARMACEUTICALS LP v. BURWELL et al
Case Number:
1:16-cv-01336
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
- Axinn Veltrop
- Covington & Burling
- Crowell & Moring
- Hyman Phelps
- Merchant & Gould
- Perkins Coie
- Rakoczy Molino
- Taft Stettinius
- Winston & Strawn
Companies
- Apotex Inc.
- AstraZeneca PLC
- Aurobindo Pharma Ltd.
- Glenmark Pharmaceuticals Ltd.
- Par Pharmaceutical Cos. Inc.
- Sun Pharmaceutical Industries Ltd.
Government Agencies
Sectors & Industries:
-
July 19, 2016
AstraZeneca Loses Bid To Keep FDA OK From Generic Crestor
A Washington, D.C., federal judge on Tuesday rejected AstraZeneca's bid for a temporary restraining order in its suit against the U.S. Food and Drug Administration and many generic drug companies seeking to block generic versions of its cholesterol medication Crestor from hitting the market.
-
July 06, 2016
FDA Assails AstraZeneca's Attack On Crestor Generics
The U.S. Food and Drug Administration urged a D.C. federal court Tuesday to toss an AstraZeneca suit aimed at blocking Crestor generics, labeling it a "transparent and manifestly premature attempt" to derail lower-cost competition with the company's cholesterol drug.
-
June 27, 2016
AstraZeneca Sues FDA To Stop Crestor Generics
AstraZeneca Pharmaceuticals LP is suing the U.S. Food and Drug Administration to stop a wave of generic versions of its cholesterol treatment Crestor from hitting the market next month when its exclusivity on the drug expires, according to a case filed Monday in Washington, D.C.